These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 24477328

  • 21. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
    Lismond A, Carbonnelle S, Verhaegen J, Schatt P, De Bel A, Jordens P, Jacobs F, Dediste A, Verschuren F, Huang TD, Tulkens PM, Glupczynski Y, Van Bambeke F.
    Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497
    [Abstract] [Full Text] [Related]

  • 22. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H, File TM, Mandell L, Ball P, Pypstra R, Thomas M, 185 Gemifloxacin Study Group.
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae.
    van Rensburg D, Fogarty C, De Salvo MC, Rangaraju M, Nusrat R.
    J Infect; 2005 Oct; 51(3):201-5. PubMed ID: 16230216
    [Abstract] [Full Text] [Related]

  • 25. Intravenous azithromycin.
    Garey KW, Amsden GW.
    Ann Pharmacother; 1999 Feb; 33(2):218-28. PubMed ID: 10084418
    [Abstract] [Full Text] [Related]

  • 26. [A multicentre study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China].
    Liu YN, Chen MJ, Zhao TM, Wang H, Wang R, Liu QF, Cai BQ, Cao B, Sun TY, Hu YJ, Xiu QY, Zhou X, Ding X, Yang L, Zhuo JS, Tang YC, Zhang KX, Liang DR, Lü XJ, Li SQ, Liu Y, Yu YS, Wei ZQ, Ying KJ, Zhao F, Chen P, Hou XN.
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jan; 29(1):3-8. PubMed ID: 16638292
    [Abstract] [Full Text] [Related]

  • 27. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan.
    Ishida T, Maniwa K, Kagioka H, Hirabayashi M, Onaru K, Tomioka H, Hayashi M, Tomii K, Gohma I, Ito Y, Hirai T, Ito I, Mishima M.
    Respirology; 2008 Mar; 13(2):240-6. PubMed ID: 18339022
    [Abstract] [Full Text] [Related]

  • 28. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM, Risso K, Hyvernat H, Landraud L, Vassallo M, Dellamonica J, de Salvador F, Cua E, Bernardin G.
    Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan.
    Izumikawa K, Watanabe A, Miyashita N, Ishida T, Hosono H, Kushimoto S, Kohno S.
    J Infect Chemother; 2014 Sep; 20(9):549-57. PubMed ID: 24934887
    [Abstract] [Full Text] [Related]

  • 30. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
    Pandya M, Chakrabarti A, Rathy S, Katoch R, Venkataraman R, Bhateja P, Mathur T, Kumar GR, Malhotra S, Rao M, Bhadauria T, Barman TK, Das B, Upadhyay D, Bhatnagar PK.
    Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
    [Abstract] [Full Text] [Related]

  • 31. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M, Mandell LA, Vrooman PS, Andrews CP, McIvor A, Abdulla RH, de Caprariis PJ, Knirsch CA, Amsden GW, Niederman MS, Lode H.
    Treat Respir Med; 2004 Aug; 3(5):329-36. PubMed ID: 15606222
    [Abstract] [Full Text] [Related]

  • 32. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG.
    Arch Intern Med; 2000 May 22; 160(10):1399-408. PubMed ID: 10826451
    [Abstract] [Full Text] [Related]

  • 33. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
    Barberán J, Mensa J.
    Rev Esp Quimioter; 2009 Sep 22; 22(3):144-50. PubMed ID: 19662548
    [Abstract] [Full Text] [Related]

  • 34. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C.
    J Lab Clin Med; 2004 May 22; 143(5):269-83. PubMed ID: 15122171
    [Abstract] [Full Text] [Related]

  • 35. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R.
    J Antimicrob Chemother; 2009 Mar 22; 63(3):511-9. PubMed ID: 19174454
    [Abstract] [Full Text] [Related]

  • 36. [Efficacy and safety of azithromycin prophylaxis of respiratory tract infections in military community].
    Guchev IA, Klochkov OI, Ivanitsa GV, Pervov IuA, Shturmina SM, Rosman SV.
    Antibiot Khimioter; 2004 Mar 22; 49(8-9):34-5, 37-42. PubMed ID: 15727144
    [Abstract] [Full Text] [Related]

  • 37. Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy.
    Miyashita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Ogasawara K, Kiyota H, Watanabe A.
    J Infect Chemother; 2017 Nov 22; 23(11):727-732. PubMed ID: 28951197
    [Abstract] [Full Text] [Related]

  • 38. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D, Jamieson BD.
    Clin Infect Dis; 2016 Oct 15; 63(8):1007-1016. PubMed ID: 27448679
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).
    Morrissey I, Leakey A.
    J Antimicrob Chemother; 2012 Jun 15; 67(6):1408-12. PubMed ID: 22357801
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.